Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05950503

Role of MRI in the Evaluation of Hepatic Metastases of Colorectal Cancer

This study wants to evaluate the use of MRI in the managemente of mCRC with liver only metastases.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Policlinico Agostino Gemelli

Roma, Italy

Location status: Recruiting

Location contact

Lisa Salvatore, MD, PhD

CONTACT

[email protected]

0630156318

About this study

This study wants to evaluate the use of MRI in the managemente of mCRC with liver only metastases.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years;
  • Histological diagnosis of colorectal cancer;
  • Presence of liver metastases in the staging exams (chest-abdomen CT with contrast medium or PET-CT with 18-FDG);
  • At least one measurable liver lesion according to RECIST 1.1 criteria;
  • Adequate organ and marrow function.

Exclusion criteria

  • Age < 18 years;
  • Inability to undergo MRI;
  • Major contraindications to liver surgery;
  • No written informed consent.

Treatment and study plan

Hepatic MRI

Radiation

The patients will undergo hepatic MRI in pre-established timepoints

Primary outcomes

  1. Surgery conversion rates

    Time frame: 3 years

    Negative conversion rate is: patients initially considered operable and subsequently not considered suitable for surgery compared to the total number of patients enrolled.

    Positive conversion rate is: patients initially deemed ineligible for surgery and subsequently operated, compared to the total number of patients enrolled.

Secondary outcomes

  1. Overall survival

    Time frame: 3 years

    Time from enrollment to death

Study contacts

Contact information is provided by the study sponsor or research team.

Lisa Salvatore, MD, PhD

CONTACT

[email protected]

0630156318

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Single-center Ambispective Observational Study on the Role of Magnetic Resonance Imaging (MRI) in the Evaluation of Patient Affected by Hepatic Metastases of Carcinoma of the

Acronym: RMN-CRC

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Jul 18, 2023
Registry last updated
Sep 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.